Dec 8 (Reuters) – Mirum Pharmaceuticals said on Monday it will acquire Bluejay Therapeutics in a deal worth up to $820 million, adding a late-stage experimental drug for a severe liver disease to its portfolio.

Under the agreement, Mirum will pay $250 million in cash and $370 million in stock upfront, plus up to $200 million in potential sales-based milestone payments.

“This acquisition fits squarely with what we do best – advancing high-impact medicines for patients with rare diseases,” said Mirum CEO Chris Peetz.

The deal will give Mirum worldwide rights to brelovitug, a monoclonal antibody being tested for chronic hepatitis D, a rare and aggressive liver condition that affects about 230,000 people in the United States and Europe and currently has no approved therapies.

Hepatitis D i

See Full Page